Hasil Pencarian - Sabine Blum
- Menampilkan 1 - 15 hasil dari 15
-
1
The Evolving Treatment Landscape of AML oleh Sabine Blum, Ulrike Bacher, Thomas Pabst
Diterbitkan 2022-03-01
Artikel -
2
The Evolving Treatment Landscape of AML oleh Sabine Blum, Ulrike Bacher, Thomas Pabst
Diterbitkan 2022-03-01
Artikel -
3
-
4
Postpartum hemorrhage risk is driven by changes in blood composition through pregnancy oleh Matthew R. Robinson, Marion Patxot, Miloš Stojanov, Sabine Blum, David Baud
Diterbitkan 2021-09-01
Artikel -
5
Isolated skin infiltration by a blastic plasmacytoid dendritic cell neoplasm oleh Grégoire Stalder, Dina Milowich, Sabine Blum, Jacqueline Schoumans, Bettina Bisig, Olivier Spertini
Diterbitkan 2022-02-01
Artikel -
6
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemi... oleh Sophie Voruz, Sabine Blum, Laurence de Leval, Jacqueline Schoumans, Françoise Solly, Olivier Spertini
Diterbitkan 2021-12-01
Artikel -
7
Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes oleh Vasiliki Papadopoulou, Jacqueline Schoumans, Valentin Basset, Françoise Solly, Jérôme Pasquier, Sabine Blum, Olivier Spertini
Diterbitkan 2023-12-01
Artikel -
8
-
9
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma oleh Sophie Voruz, Anne Cairoli, Olaia Naveiras, Laurence de Leval, Edoardo Missiaglia, Krisztian Homicsko, Olivier Michielin, Sabine Blum
Diterbitkan 2018-01-01
Artikel -
10
Comment on “MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma” oleh Sophie Voruz, Filipe Martins, Anne Cairoli, Olaia Naveiras, Krisztian Homicsko, Edoardo Missiaglia, Laurence de Leval, Bettina Bisig, Olivier Michielin, Sabine Blum
Diterbitkan 2018-03-01
Artikel -
11
P361: HIGH REMISSION AND SURVIVAL RATE IN ADULTS WITH MINIMAL RESIDUAL DISEASE-POSITIVE OR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH BLINATUMOMAB IN ROU... oleh Sabina Chiaretti, Sabine Blum, Thibaut Leguay, Marie Balsat, Cyril Salek, Nicola Fracchiolla, Alexandros Spyridonidis, Anita Rijneveld, Cristina Papayannidis, Sofia Ganzha, Reetabrata Bhattacharyya, Gerhard Zugmaier, Isabella Pezzani Grueter, Andreas Ochs, Alessandro Rambaldi
Diterbitkan 2023-08-01
Artikel -
12
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced... oleh Jeanne Mendell, Daniel J. Freeman, Wenqin Feng, Thore Hettmann, Matthias Schneider, Sabine Blum, Jens Ruhe, Johannes Bange, Kenji Nakamaru, Shuquan Chen, Zenta Tsuchihashi, Joachim von Pawel, Catherine Copigneaux, Robert A. Beckman
Diterbitkan 2015-03-01
Artikel -
13
Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leuk... oleh Sabine Blum, Yves Chalandon, Myriam Labopin, Jürgen Finke, Tobias Gedde-Dahl, Tarek Ben Othman, Jan J. Cornelissen, Pavel Jindra, Hélène Labussière-Wallet, Matthew Collin, Stig Lenhoff, Guido Kobbe, Norma C. Gutiérrez, Arnon Nagler, Mohamad Mohty
Diterbitkan 2024-03-01
Artikel -
14
P315: TP53 ALTERATIONS AND MRD REFINE PROGNOSIS OF ADULT KMT2A-REARRANGED B-ALL oleh Rathana Kim, Hugo Bergugnat, Florence Pasquier, Emmanuel Raffoux, Lise Larcher, Marie Passet, Cedric Pastoret, Grardel Nathalie, Vahid Asnafi, Eric Delabesse, Aurélie Caye-Eude, Claus Meyer, Rolf Masrschalek, Anne Thiebaut-Bertrand, Marie Balsat, Martine Escoffre, Sabine Blum, Michael Baumann, Anne Banos, Nicole Straetmans, Maria Pilar Gallego Hernanz, Yves Chalandon, Carlos Graux, Thibaut Leguay, Mathilde Hunault, Françoise Huguet, Véronique Lhéritier, Jean Soulier, Nicolas Boissel, Emmanuelle Clappier
Diterbitkan 2023-08-01
Artikel -
15
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine oleh Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls
Diterbitkan 2023-06-01
Artikel